Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models

Leukemia and Lymphoma

Volumn 43, Issue 8, 2002, Pages 1549-1561

  Ren, Ruibao ^a  

^a BRANDEIS UNIVERSITY   (United States)

Author keywords

BCR ABL; Chronic myelogenous leukemia (CML); Murine model

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CYTOKINE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; IMATINIB; INTERLEUKIN 3; INTERLEUKIN 7; MYC PROTEIN; NEUROTROPHIN 3 RECEPTOR; ONCOPROTEIN; ONCOSTATIN M; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLECKSTRIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P185; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAC PROTEIN; RAF PROTEIN; RAS PROTEIN; SOS PROTEIN; STAT5B PROTEIN; STEM CELL FACTOR; TRANSCRIPTION FACTOR; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CHROMOSOME 14P; CHROMOSOME 9P; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HEMATOPOIESIS; HUMAN; IN VIVO STUDY; LEUKEMOGENESIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION; DISEASE MODEL; GENETICS; LYMPHOCYTE ACTIVATION; MYELOPROLIFERATIVE DISORDER; PHYSIOLOGY; RETROVIRUS; REVIEW; SRC HOMOLOGY DOMAIN; XENOGRAFT;

ANIMAL; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DISEASE MODELS, ANIMAL; FUSION PROTEINS, BCR-ABL; HUMAN; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE ACTIVATION; MICE; MYELOPROLIFERATIVE DISORDERS; RETROVIRIDAE; SRC HOMOLOGY DOMAINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSPLANTATION, HETEROLOGOUS; ANIMALS; HUMANS;

EID: 0036020955     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000002875     Document Type: Article

References (107)

1. "The biology of chronic myeloid leukemia"
2. "The molecular genetics of Philadelphia chromosome-positive leukemias"
3. "BCR-ABL gene variants"
4. "Chronic myeloid disorders: Classification and treatment overview"
5. "The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues."
6. "The molecular biology of chronic myeloid leukemia"
7. "Chronic myeloid leukemia"
8. "Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors"
9. "Signal transduction by wild-type and leukemogenic Ab1 proteins"
10. "The viral and cellular forms of the abelson (abl) oncogene"
11. "N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl"
12. "Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential"
13. "Signaling pathways activated by oncogenic forms of Abl tyrosine kinase"
14. "Tyrosine kinase activity and transformation potency of bcr-abl oncogene products"
15. "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells"
16. "Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia"
17. "Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylamino-pyrimidine derivative"
18. "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor"
19. "Chronic myelogenous leukemia"
20. "Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification"
21. "Signal transduction pathways involved in BCR-ABL transformation"
22. "Integrin-mediated regulation of hematopoiesis: Do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?"
23. "Growth factor independence and BCR/ABL transformation: Promise and pitfalls of murine model systems and assays"
24. "Retroviral transduction models of ph(+) leukemia: Advantages and limitations for modeling human hematological malignancies in mice"
25. "Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a"
26. "Creation of human tumour cells with defined genetic elements"
27. "High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase"
28. "Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34 + cells"
29. "A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL- containing retroviral vector"
30. "Modeling Philadelphia chromosome positive leukemias"
31. "Human bcr-abl gene has a lethal effect on embryogenesis"
32. "Acute leukemia in bcr/abl transgenic mice"
33. "Restricted oncogenicity of BCR/ABL p190 in transgenic mice"
34. "BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice"
35. "Expression of p210bcr-abl by metallothionein promoter induced T-cell leukemia in transgenic mice"
36. "Reveribility of acute B-cell leukemia induced by BCR-ABL1"
37. "A BCR-ABL(p190) fusion gene made by homologous recombination causes B- cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product"
38. "Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: A novel transgenic model for human Ph1-Positive leukemias"
39. "Conditional gene targeting"
40. "Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome"
41. "Bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice"
42. "Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL"
43. "Efficient transplantation of Bcr-Abl-induced chronic myelogenous leukemia-like syndrome in mice"
44. "Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow"
45. "The P190, P210, and P230 Forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity"
46. "High-titer retroviral vectors for efficient transduction of functional genes into murine hematopoietic stem cells"
47. "Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions"
48. "A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins"
49. "The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl"
50. "Autoinhibition of c-Abl"
51. "Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy"
52. "Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells in vivo"
53. "Protein modules and signalling networks"
54. "Differential complementation of Bcr-Abl point mutants with c-Myc"
55. "Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene"
56. "Structural and signaling requirements for Bcr-Abl-mediated transformation and inhibition of apoptosis"
57. "The SH2 domain of Abl is not required for factor-independent growth induced by Bcr-Abl in a murine myeloid cell line"
58. "The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells"
59. "The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype"
60. "The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase"
61. "The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity"
62. "Expression of ICSBP is downregulated in Bcr-Abl-induced murine CML-like disease, and forced coexpression of ICSBP inhibits the Bcr-Abl-induced myeloproliferative disorder"
63. "Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5"
64. "BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb-2 adaptor protein"
65. "The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase"
66. "The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event"
67. "Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia"
68. "Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses"
69. "Antiapoptotic activity of stat5 required during terminal stages of myeloid differentiation"
70. "Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: A direct role for Stat5 in Bcl-X(L) induction"
71. "Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway"
72. "Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation"
73. "Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2)"
74. "Fusion of H4/D10S170 to the platelet derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21)"
75. "Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia"
76. "FGFR1 and MOZ, two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8p11-12"
77. "The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: Transforming activity and specific inhibition of FGFR1 fusion proteins"
78. "Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells"
79. "A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation"
80. "Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25)"
81. "Point mutations in the FLT3 gene in AML"
82. "Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy"
83. "Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes"
84. "TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor"
85. "Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia"
86. "FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model"
87. "Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581"
88. "Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2"
89. "Oncostatin M: Signal transduction and biological activity"
90. "Mouse oncostatin M: An immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway"
91. "Granulocyte-macrophage colony stimulating factor and interleukin-6 enhanced white blood cell synthesis of leukotrienes in chronic myelogenous leukemia"
92. "Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors"
93. "Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia"
94. "Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL"
95. "Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony- stimulating factor or interleukin-3"
96. "NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia"
97. "Blast crisis in a murine model of chronic myelogenous leukemia"
98. "Acquired loss of p53 induces blastic transformation in p210bcr/abl-expressing hematopoietic cells: A transgenic study for blast crisis of human CML"
99. "Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A novel model for human AML"
100. "Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis"
101. "Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene"
102. "AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis"
103. "Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors"
104. "Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor"
105. "Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11"
106. "Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia"
107. "The hallmarks of cancer"